Marketing medicines through randomised controlled trials: the case of interferon

Research output: Contribution to journalSpecial issueAcademicpeer-review

Abstract

Randomised clinical trials are regarded as a most helpful tool to relieve medical practice of subjectivity. Interferon became a part of everyday clinical practice through randomised clinical trials. Despite initial disappointment with its clinical efficacy, interferon became legitimised as a part of medical practice. Randomised clinical trials had the side effect of widening interferon's therapeutic profile and were central to the marketing strategies of pharmaceutical companies. The use and interpretation of randomised clinical trials differ substantially for experimental drugs in serious illness and for research into less serious diseases
Original languageEnglish
Pages (from-to)1231-1233
Number of pages3
JournalBritish Medical Journal
Volume317
Issue number7167
DOIs
Publication statusPublished - 31 Oct 1998

Keywords

  • interferon
  • neoplasm
  • clinical practice
  • clinical trial
  • controlled clinical trial
  • drug efficacy
  • drug industry
  • drug marketing
  • human
  • medical research
  • priority journal
  • randomized controlled trial
  • short survey
  • virus infection

Fingerprint

Dive into the research topics of 'Marketing medicines through randomised controlled trials: the case of interferon'. Together they form a unique fingerprint.

Cite this